- Home
- BPRN vs TLSI Comparison
BPRN vs TLSI Comparison
Compare BPRN & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BPRN | TLSI |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.5M | 244.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BPRN | TLSI |
|---|---|---|
| Price | $33.96 | $7.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $35.00 | $10.67 |
| AVG Volume (30 Days) | 8.2K | ★ 155.3K |
| Earning Date | 10-29-2025 | 11-13-2025 |
| Dividend Yield | ★ 4.20% | N/A |
| EPS Growth | ★ 62.30 | N/A |
| EPS | ★ 2.57 | N/A |
| Revenue | ★ $76,577,000.00 | $40,207,000.00 |
| Revenue This Year | $13.51 | $55.06 |
| Revenue Next Year | $6.01 | $46.04 |
| P/E Ratio | $12.95 | ★ N/A |
| Revenue Growth | 13.94 | ★ 49.52 |
| 52 Week Low | $27.25 | $3.42 |
| 52 Week High | $38.78 | $7.32 |
Technical Indicators
Market Signals| Indicator | BPRN | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 56.91 | 74.64 |
| Support Level | $33.41 | $6.06 |
| Resistance Level | $33.95 | $7.32 |
| Average True Range (ATR) | 0.71 | 0.55 |
| MACD | -0.01 | 0.18 |
| Stochastic Oscillator | 60.49 | 91.91 |
Price Performance
Historical ComparisonAbout BPRN Princeton Bancorp Inc. (PA)
Princeton Bancorp Inc is a banking company. It is a full-service financial institution that provides business and personal banking. Its personal banking and business banking services include checking accounts and savings accounts. It offers traditional retail banking services, one-to-four-family residential mortgage loans, multi-family and commercial mortgage loans, construction loans, commercial business loans, and consumer loans, including home equity loans and lines of credit. The Bank also has two retail branches and conducts loan origination activities in select areas of the New York City metropolitan area.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.